The Medical Research Agency (MRA) published its Activity Plan for 2025, outlining strategic priorities for the development of biomedical research and innovation in Poland. The document was developed in consultation with the MRA Council, the Ministry of Health and based on extensive analyses of current healthcare and research needs.
The Plan presents key information on planned funding calls, agency-led projects, digital health initiatives, international cooperation and programmes supporting researchers and healthcare professionals.
The Medical Research Agency announced an open call for non-commercial clinical trials of medicinal products (ABM/2025/1). The primary objective of the call was to support studies evaluating medicinal products and identifying the most clinically effective therapeutic approaches across a broad spectrum of diseases.
Particular emphasis was placed on rare diseases, paediatric conditions and neurological disorders. Projects submitted under the call were required to meet the definition of a non-commercial clinical trial of a medicinal product.
According to the competition regulations, a single applicant or consortium leader could submit a maximum of three applications and participate as a consortium member in no more than three additional applications, provided that each application concerned a different medicinal product.
As a single institution, the Medical University of Gdańsk was eligible to participate in a maximum of six applications. Internal project preselection procedures were therefore introduced in accordance with Rector’s Ordinance No. 72/2024.
To support potential applicants, the Clinical Research Support Centre organised consultation meetings and provided a set of supporting documents, including:
CWBK also offered online consultations for researchers interested in preparing proposals.
The MRA Activity Plan for 2025 highlighted the growing importance of non-commercial clinical research, international collaboration and healthcare digitalisation. The document provided a strategic framework for research institutions planning to apply for MRA funding and expand their clinical research activities.
It also reinforced the role of Clinical Research Support Centres in facilitating the preparation and implementation of high-quality research projects.